GLP-1 / GIP receptor agonists and targeted lipolytic peptides for metabolic recomposition · used inside a supervised lifestyle and lab-monitored plan.
Helps reduce dangerous visceral (belly) fat
Stabilized GHRH analog with documented reduction of visceral adipose tissue and improvement in lipid profile.
FDA-approved; off-label use requires clinician judgment.
Cautions: Monitor glucose and IGF-1 · Avoid in active malignancy · Avoid pregnancy
Clinically proven weight loss support
GLP-1 receptor agonist. Slows gastric emptying, enhances glucose-dependent insulin secretion, reduces appetite.
FDA-approved.
Cautions: Personal/family history of medullary thyroid carcinoma or MEN-2 · Pancreatitis history · GI side effects common
Powerful weight loss support
Dual GIP/GLP-1 receptor agonist. Greater weight-loss efficacy than mono-agonists.
FDA-approved.
Cautions: Same boxed warnings as semaglutide · Gallbladder disease risk
Supports targeted fat release
Synthetic fragment (hGH 176–191) that mimics GH lipolytic activity without affecting IGF-1 or glucose.
Research / compounding only in most jurisdictions.
Cautions: Limited long-term safety data
May improve metabolic flexibility
Small-molecule NNMT inhibitor. Restores intracellular SAM and NAD+, promoting adipocyte energy expenditure.
Research only.
Cautions: Investigational; human data lacking
Every protocol is reviewed by an independent, licensed physician before any recommendation is issued.
We only prescribe therapies that are legally available where you live, through compliant pharmacies.
Your medical intake and blood panel are screened for conditions that would make a peptide unsafe.
Protocols are adjusted based on objective lab change. If a marker is not improving, we change the plan.
The €90 intake returns a clinician-reviewed brief in 48 hours. Full protocol · €320.
Start assessment →